Nuvo Pharmaceuticals Inc
F:23N
Nuvo Pharmaceuticals Inc
F:23N
Price:
0.9
EUR
-1.64%
Market Closed
Market Cap:
€10.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Nuvo Pharmaceuticals Inc
F:23N
|
CA |
|
B
|
Ball Corp
F:BL8
|
US |
|
I
|
Inter Parfums Inc
F:JF1
|
US |
|
O
|
Opendoor Technologies Inc
F:25M
|
US |
|
Basf Se
F:BAS
|
DE |
|
C
|
CECO Environmental Corp
NASDAQ:CECO
|
US |
|
T
|
Thomson Reuters Corp
F:TOCB
|
CA |
|
K
|
KCE Electronics PCL
SET:KCE
|
TH |
|
C
|
China Resources Land Ltd
F:CHZ
|
HK |
|
Fidus Investment Corp
NASDAQ:FDUS
|
US |
|
V
|
Vita 34 AG
OTC:VTIAF
|
DE |
|
C
|
Cognizant Technology Solutions Corp
F:COZ
|
US |
|
O
|
Oversea-Chinese Banking Corporation Ltd
F:OCBA
|
SG |
|
Erlebnis Akademie AG
XETRA:EAD
|
DE |
|
Liberty Global Ltd
F:3O40
|
BM |
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 23N's stock price target?
Not Available
23N does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Nuvo Pharmaceuticals Inc?
Projected CAGR
79%
79%
Over the last 8 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 12 years is 79%.
What is the Operating Income forecast for Nuvo Pharmaceuticals Inc?
Projected CAGR
170%
170%
The compound annual growth rate for Operating Income over the next 7 years is 170%.
